License Revenue - Related Party was Dianthus Therapeutics’s largest revenue line in fiscal 2024, bringing in $5.91M of $6.24M (95%).
| Related and Nonrelated Parties | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Zenas Biopharma Limited | $6.40M | — | — |
| License Revenue - Related Party | — | $2.83M | $5.91M |
| Related Party | $6.42M | — | — |
| Nonrelated Party | — | — | $326.00K |
| Total | $12.82M | $2.83M | $6.24M |
Dianthus Therapeutics brought in $6.24M from its two revenue lines in fiscal 2024, the year ended December 31, 2024. Dianthus Therapeutics regrouped these revenue lines after fiscal 2023, so the total does not compare directly with that year's $2.83M. License Revenue - Related Party was the largest at $5.91M (94.8%), ahead of Nonrelated Party at $326.00K (5.2%).
Dianthus Therapeutics began breaking out License Revenue - Related Party in fiscal 2023 and Nonrelated Party in fiscal 2024. Dianthus Therapeutics stopped reporting Related Party ($6.42M in fiscal 2022) and Zenas Biopharma Limited ($6.40M in fiscal 2022) as separate revenue lines.
Dianthus Therapeutics (DNTH) reports its revenue by related and nonrelated parties. In fiscal 2024, License Revenue - Related Party was its largest revenue line, bringing in $5.91M (94.8% of the total), followed by Nonrelated Party at $326.00K (5.2%).
License Revenue - Related Party was Dianthus Therapeutics' largest revenue line in fiscal 2024, bringing in $5.91M, or 94.8% of the $6.24M total across its two revenue lines.
Every figure comes from Dianthus Therapeutics' annual financial filings, as reported. Each line keeps the name Dianthus Therapeutics gives it, and years follow its fiscal calendar.
Dianthus Therapeutics' revenue by related and nonrelated parties goes back to fiscal 2022, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.